Clinical Trial: Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620561) titled 'Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients' on May 26.

Brief Summary: The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Prurigo Nodularis (PN)

Intervention: DRUG: Lebrikizumab

Participants will receive subcutaneous injections of Lebrikizumab every two weeks for 24 weeks. The first two doses will be 500 mg, and following doses will be 250 mg.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University of Maryland, Baltimore ...